Melinta Therapeutics, Inc. (MLNT): Price and Financial Metrics


Melinta Therapeutics, Inc. (MLNT)

Today's Latest Price: $0.44 USD

0.06 (-12.00%)

Updated Jan 13 7:51pm

Add MLNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

MLNT Stock Summary

  • Melinta Therapeutics Inc's stock had its IPO on November 6, 2017, making it an older stock than merely 4.99% of US equities in our set.
  • The volatility of Melinta Therapeutics Inc's share price is greater than that of 95.22% US stocks with at least 200 days of trading history.
  • Melinta Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -183.63%, greater than the shareholder yield of just 2.18% of stocks in our set.
  • Stocks that are quantitatively similar to MLNT, based on their financial statements, market capitalization, and price volatility, are FORTY, COMM, ISR, NEOS, and SORL.
  • Visit MLNT's SEC page to see the company's official filings. To visit the company's web site, go to www.melinta.com.
MLNT Daily Price Range
MLNT 52-Week Price Range

MLNT Stock Price Chart More Charts


MLNT Price/Volume Stats

Current price $0.44 52-week high $10.10
Prev. close $0.50 52-week low $0.31
Day low $0.31 Volume 1,107,200
Day high $0.46 Avg. volume 785,675
50-day MA $1.50 Dividend yield N/A
200-day MA $3.17 Market Cap 6.05M

Melinta Therapeutics, Inc. (MLNT) Company Bio


Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.


MLNT Latest News Stream


Event/TimeNews Detail
Loading, please wait...

MLNT Latest Social Stream


Loading social stream, please wait...

View Full MLNT Social Stream

MLNT Price Returns

1-mo N/A
3-mo N/A
6-mo -74.71%
1-year -79.25%
3-year -99.55%
5-year -99.95%
YTD -17.15%
2019 -86.55%
2018 -95.00%
2017 12.86%
2016 -91.01%
2015 32.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8494 seconds.